Archive for 2010
Fibrocell Science, Inc. Submits Complete Response to FDA Regarding Azficel-T
Fibrocell Science, Inc. Submits Complete Response to FDA Regarding Azficel-T EXTON, Pa., Demember 20, 2010 – Fibrocell Science, Inc. (OTCBB: FCSC), a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has submitted its complete response to the Complete Response (CR) letter issued byRead more
Fibrocell Science, Inc. Reports Third Quarter 2010 Financial Results and Provides Business Update
Fibrocell Science, Inc. Reports Third Quarter 2010 Financial Results and Provides Business Update EXTON, Pa., November 17, 2010 – Fibrocell Science, Inc. (OTCBB: FCSC), a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced a financial and business update for the third quarter ended September 30, 2010.Read more
Fibrocell Science, Inc. to Present at the Maxim Group Growth Conference
EXTON, Pa., November 10, 2010 – Fibrocell Science, Inc. (OTCBB: FCSC), a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that David M. Pernock, the Company’s Chairman and CEO, will be presenting at the Maxim Group Growth Conference to be held on Thursday, November 18,Read more
Fibrocell Science, Inc. Establishes Joint Venture to Market Its Technology Platform in Asia
Agreement to provide Fibrocell with access to large and growing aesthetic market in Asia EXTON, Pa., November 3, 2010 – Fibrocell Science, Inc. (OTCBB: FCSC), a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has signed an agreement to establish a joint ventureRead more
Fibrocell Science, Inc. Names Biotechnology and Genetic Research Expert Stefan Gruenwald, M.D., Ph.D., to Scientific Advisory Board
EXTON, Pa., September 7, 2010 – Fibrocell Science, Inc. (OTCBB: FCSC), a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today the appointment of Stefan Gruenwald, M.D., Ph.D., to its scientific advisory board. In addition to being a renowned molecular and cellular biologist, Dr. Gruenwald isRead more
Fibrocell Science, Inc. to Present at the 2010 Global Hunter Securities Healthcare Conference
EXTON, Pa., August 11, 2010 – Fibrocell Science, Inc. (OTCBB: FCSC), a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that David Pernock, Chairman and Chief Executive Officer, will present at the 2010 Global Hunter Securities Healthcare Conference at the Southern California Investor Conference onRead more
Fibrocell Science, Inc. Submits CSR to U.S. Food and Drug Administration for Phase II/III Trial of Azficel-T in Acne Scarring
Further Study Analysis in CSR Confirms Topline Results from Clinical Trial EXTON, Pa., August 9, 2010 – Fibrocell Science, Inc. (OTCBB: FCSC), a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has submitted a clinical study report for its Phase II/III study ofRead more
Fibrocell Science, Inc. Announces Addition of Dr. George J. Korkos to Board of Directors
EXTON, Pa., July 20, 2010 – Fibrocell Science, Inc. (OTCBB: FCSC), a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that George J. Korkos, M.D., D.D.S., F.A.C.S., has been appointed to its board of directors. Dr. Korkos currently serves as President of both Plastic SurgeryRead more
Fibrocell Science, Inc. Completes Enrollment and First Treatment Visits for Histology Study of azficel-T
EXTON, Pa., July 08, 2010 – Fibrocell Science, Inc. (OTCBB: FCSC), a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today the completion of enrollment of and first treatment visits for participants in its histology study (IT-H-001) of azficel-T. An autologous cell therapy, azficel-T is currentlyRead more
Fibrocell Science, Inc. Appoints Advisors with Expertise in Periodontal/ Regenerative Dentistry and Burn Care
- Company Continues Evaluation of Broad Use of Proprietary Autologous Cell Therapy – EXTON, Pa., June 24, 2010 – Fibrocell Science, Inc. (OTCBB: FCSC), a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today the appointments of Nicolas Elian, D.D.S.; William K. Boss, M.D.; and DanielRead more